ASH Conference Coverage
Featured Articles
(Reuters) Dec 9, 2019 - Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. The lowest dose of the therapy, bb21217, had a median duration of response of...
Read Article
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Researchers say the...
Read Article
Latest Articles
December 12, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
December 10, 2019
View More
News Commentary
There is no ASH Conference Coverage commentary.

OBR Blog
As the ASH Annual Meeting concludes, the late-breaking abstracts are always of great interest. We take a brief look at... Read more
December 04, 2018
As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two studies that have the... Read more
December 04, 2018

OBR Tweets

May 26
H. Jack West, MD: Another option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib… https://t.co/k9fEkGefkq

May 26
H. Jack West, MD: Elderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse eff… https://t.co/qvJRVE5FyX

May 22
A recent FDA workshop delved into liquid biopsy screening approaches as they are increasingly being applied, partic… https://t.co/ZC83sOvoO2

May 21
H. Jack West, MD: While it's always nice to have another option, it's hard for me to see how atezolizumab provides… https://t.co/TUgQMgLwcA

May 21
Tomasz M. Beer, MD: PAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patien… https://t.co/V0TnoRIDfR

May 20
At the #aacr2020 Virtual Meeting I, there was pivotal data from immunotherapy triplet trials in breast cancer, mela… https://t.co/eJ1m97OA6G

May 20
The emergence of #COVID-19 has transformed the care of cancer patients and upended the way practices do business. D… https://t.co/yLcc5dTpjn

May 19
At @oncologyCOA's first virtual conference, presenters discussed modernizing the clinical trial process, the comple… https://t.co/VIBVh1b8bA

May 19
Join us Tonight, May 19th 7:30 ET for a webinar discussing the unique management of advanced hepatocellular carcino… https://t.co/lgdd4xzlDb

May 19
H. Jack West, MD: I imagine that the nivolumab/ipilumumab combination will have some appeal to patients or physicia… https://t.co/faXlyOvMeC